We would like to inform you that we have completed the first part of the study with a single, escalating dose (FIH, SAD) (Part A), of the innovative antidiabetic drug.

 

We would like to inform you that we have completed the first part of the study with a single, escalating dose (FIH, SAD) (Part A), of the innovative antidiabetic drug. The project was implemented in cooperation with a Polish pharmaceutical company. The new therapy aims to reduce insulin resistance and to regulate the chronic high blood glucose level. Due to the state of the pandemic, the study was conducted in accordance with the highest sanitary standards as well as procedures related to the monitoring of the epidemic state. This approach, combined with the principles of GCP, ensured the safety and well-being of our patients. Soon we are starting the second part of the study (hello B0) with multiple, escalating dose of the new drug.

Go back

News

GCLP accreditation

We are proud to announce that on February 2019 we have received a GCLP certificate which confirms our high quality of services.

Read more …

Christmas wishes

To all our Sponsors, Vendors, Employees and Co-Workers we wish joy and happiness for the in-coming Christmas!

Read more …

Privacy Policy introduced on 25th of May 2018

On May 25, 2018, the European Union will begin to enforce more strict privacy rules under the General Data Protection Regulation (GDPR), so we have introduced new Privacy Policy.

Read more …

International Clinical Trials Day on 24th of May 2018

Our Team has participated in one of the most importants conferences regarding Clinical Trials in Poland.

Read more …

New article about EMA guidelines on FIH studies

In "Scientific Publications" tab you can find an interesting, new article about update of EMA guideline on strategies to identify and mitigate risks for first-in-human clinical trials

Read more …

About Us | Services | Our Site | Partners | Smoking Risk Study | Contact Us

Early Phase Clinical Trials

2022 © Bio Research Group. All rights reserved.

 

scroll to top ▲